Research Analysts’ Recent Ratings Changes for Inovio Pharmaceuticals (INO)

A number of research firms have changed their ratings and price targets for Inovio Pharmaceuticals (NASDAQ: INO):

• 8/13/2026 – Inovio Pharmaceuticals had its “neutral” rating reaffirmed by HC Wainwright.
• 8/13/2026 – Inovio Pharmaceuticals was upgraded by Jefferies Financial Group Inc. from “hold” to “positive”. They now have a $3.00 price target on the stock, up from $1.80.
• 8/3/2026 – Inovio Pharmaceuticals had its “overweight” rating reaffirmed by Piper Sandler. They now have a $4.00 price target on the stock.
• 7/29/2026 – Inovio Pharmaceuticals was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/1/2026 – Inovio Pharmaceuticals was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/21/2026 – Inovio Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/16/2026 – Inovio Pharmaceuticals was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.